Loading...

We've got a brand new version of Simply Wall St! Try it out

SoftOx Solutions

OB:SOFTOX-ME
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SOFTOX-ME
OB
NOK113M
Market Cap
  1. Home
  2. NO
  3. Pharmaceuticals & Biotech
Company description

SoftOx Solutions AS, together with its subsidiaries, operates as a medtech company in Norway. The last earnings update was 78 days ago. More info.


Add to Portfolio Compare Print
SOFTOX-ME Share Price and Events
7 Day Returns
-6.2%
OB:SOFTOX-ME
-2.2%
Europe Pharmaceuticals
2.6%
NO Market
1 Year Returns
-23.8%
OB:SOFTOX-ME
6.8%
Europe Pharmaceuticals
-9.1%
NO Market
SOFTOX-ME Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
SoftOx Solutions (SOFTOX-ME) -6.2% 8% 1.7% -23.8% - -
Europe Pharmaceuticals -2.2% 0.5% 2.3% 6.8% 10.1% 3.1%
NO Market 2.6% 8% 2.6% -9.1% 31.3% 13.2%
1 Year Return vs Industry and Market
  • SOFTOX-ME underperformed the Pharmaceuticals industry which returned 6.8% over the past year.
  • SOFTOX-ME underperformed the Market in Norway which returned -9.1% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

SOFTOX-ME Value

 Is SoftOx Solutions undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for SoftOx Solutions. This is due to cash flow or dividend data being unavailable. The share price is NOK24.4.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for SoftOx Solutions's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are SoftOx Solutions's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OB:SOFTOX-ME PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in NOK NOK-2.81
OB:SOFTOX-ME Share Price ** OB (2019-09-13) in NOK NOK24.4
Europe Pharmaceuticals Industry PE Ratio Median Figure of 54 Publicly-Listed Pharmaceuticals Companies 23.94x
Norway Market PE Ratio Median Figure of 149 Publicly-Listed Companies 13.32x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of SoftOx Solutions.

OB:SOFTOX-ME PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OB:SOFTOX-ME Share Price ÷ EPS (both in NOK)

= 24.4 ÷ -2.81

-8.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SoftOx Solutions is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
  • SoftOx Solutions is loss making, we can't compare the value of its earnings to the Norway market.
Price based on expected Growth
Does SoftOx Solutions's expected growth come at a high price?
Raw Data
OB:SOFTOX-ME PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 38 Publicly-Listed Pharmaceuticals Companies 1.78x
Norway Market PEG Ratio Median Figure of 110 Publicly-Listed Companies 0.72x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for SoftOx Solutions, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on SoftOx Solutions's assets?
Raw Data
OB:SOFTOX-ME PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in NOK NOK6.01
OB:SOFTOX-ME Share Price * OB (2019-09-13) in NOK NOK24.4
Europe Pharmaceuticals Industry PB Ratio Median Figure of 115 Publicly-Listed Pharmaceuticals Companies 2.87x
Norway Market PB Ratio Median Figure of 238 Publicly-Listed Companies 1.13x
OB:SOFTOX-ME PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OB:SOFTOX-ME Share Price ÷ Book Value per Share (both in NOK)

= 24.4 ÷ 6.01

4.06x

* Primary Listing of SoftOx Solutions.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SoftOx Solutions is overvalued based on assets compared to the Europe Pharmaceuticals industry average.
X
Value checks
We assess SoftOx Solutions's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. SoftOx Solutions has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SOFTOX-ME Future Performance

 How is SoftOx Solutions expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SoftOx Solutions has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.3%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is SoftOx Solutions expected to grow at an attractive rate?
  • Unable to compare SoftOx Solutions's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare SoftOx Solutions's earnings growth to the Norway market average as no estimate data is available.
  • Unable to compare SoftOx Solutions's revenue growth to the Norway market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OB:SOFTOX-ME Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 13.3%
Europe Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.7%
Norway Market Earnings Growth Rate Market Cap Weighted Average 15.1%
Norway Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OB:SOFTOX-ME Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in NOK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OB:SOFTOX-ME Past Financials Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income *
2019-03-31 6 -18 -13
2018-12-31 4 -15 -13
2018-09-30 3 -19 -10
2018-06-30 0 -20 -12
2018-03-31 0 -18 -11
2017-12-31 0 -15 -9
2016-12-31 0 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if SoftOx Solutions is high growth as no earnings estimate data is available.
  • Unable to determine if SoftOx Solutions is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OB:SOFTOX-ME Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from SoftOx Solutions Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:SOFTOX-ME Past Financials Data
Date (Data in NOK Millions) EPS *
2019-03-31 -2.81
2018-12-31 -3.42
2018-09-30 -2.75
2018-06-30 -3.08
2018-03-31 -3.05
2017-12-31 -3.78
2016-12-31 -2.85

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if SoftOx Solutions will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine SoftOx Solutions's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. SoftOx Solutions's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. SoftOx Solutions's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess SoftOx Solutions's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
SoftOx Solutions has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SOFTOX-ME Past Performance

  How has SoftOx Solutions performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare SoftOx Solutions's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • SoftOx Solutions does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare SoftOx Solutions's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare SoftOx Solutions's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
SoftOx Solutions's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from SoftOx Solutions Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:SOFTOX-ME Past Revenue, Cash Flow and Net Income Data
Date (Data in NOK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 5.61 -13.01 9.34
2018-12-31 4.32 -12.93 8.18
2018-09-30 2.83 -10.39 6.83
2018-06-30 0.17 -11.64 4.98
2018-03-31 0.00 -11.46 4.56
2017-12-31 0.00 -9.41 4.08
2016-12-31 0.10 -6.22 2.94

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if SoftOx Solutions has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if SoftOx Solutions has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if SoftOx Solutions improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess SoftOx Solutions's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
SoftOx Solutions has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SOFTOX-ME Health

 How is SoftOx Solutions's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up SoftOx Solutions's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • SoftOx Solutions is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • SoftOx Solutions has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of SoftOx Solutions's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • SoftOx Solutions has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from SoftOx Solutions Company Filings, last reported 5 months ago.

OB:SOFTOX-ME Past Debt and Equity Data
Date (Data in NOK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 27.82 0.00 8.27
2018-12-31 14.41 0.00 1.24
2018-09-30 15.95 0.00 3.25
2018-06-30 18.30 0.00 5.43
2018-03-31 22.78 0.00 11.13
2017-12-31 26.85 0.00 17.10
2016-12-31 2.48 0.00 0.30
  • SoftOx Solutions has no debt.
  • SoftOx Solutions has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • SoftOx Solutions has less than a year of cash runway based on current free cash flow.
  • SoftOx Solutions has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.6% each year.
X
Financial health checks
We assess SoftOx Solutions's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. SoftOx Solutions has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SOFTOX-ME Dividends

 What is SoftOx Solutions's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from SoftOx Solutions dividends.
If you bought NOK2,000 of SoftOx Solutions shares you are expected to receive NOK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate SoftOx Solutions's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate SoftOx Solutions's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OB:SOFTOX-ME Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 39 Stocks 3%
Norway Market Average Dividend Yield Market Cap Weighted Average of 115 Stocks 4.5%
Norway Minimum Threshold Dividend Yield 10th Percentile 1.5%
Norway Bottom 25% Dividend Yield 25th Percentile 2.5%
Norway Top 25% Dividend Yield 75th Percentile 6.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as SoftOx Solutions has not reported any payouts.
  • Unable to verify if SoftOx Solutions's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of SoftOx Solutions's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as SoftOx Solutions has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess SoftOx Solutions's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can SoftOx Solutions afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. SoftOx Solutions has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SOFTOX-ME Management

 What is the CEO of SoftOx Solutions's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Geir Almas
CEO Bio

Mr. Geir Hermod Almas serve as Chief Executive Officer at SoftOx Solutions AS.

CEO Compensation
  • Insufficient data for Geir to compare compensation growth.
  • Insufficient data for Geir to establish whether their remuneration is reasonable compared to companies of similar size in Norway.
Management Team

Geir Almas

TITLE
Chief Executive Officer

Anne Aasprong

TITLE
Chief Production Officer
Board of Directors

Kristian Almas

TITLE
Non-Executive Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NOK) Value (NOK)
06. Mar 19 Buy Beate Johnsen Individual 06. Mar 19 06. Mar 19 21,800 NOK22.00 NOK479,600
04. Jan 19 Buy Geir Almas Individual 04. Jan 19 04. Jan 19 91,000 NOK22.00 NOK2,002,000
04. Jan 19 Buy Kristian Almas Individual 04. Jan 19 04. Jan 19 286,805 NOK22.00 NOK6,309,711
04. Jan 19 Buy Glenn Gundersen Individual 04. Jan 19 04. Jan 19 7,500 NOK22.00 NOK165,000
04. Jan 19 Buy Lars Frigstad Individual 04. Jan 19 04. Jan 19 16,000 NOK22.00 NOK352,000
X
Management checks
We assess SoftOx Solutions's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. SoftOx Solutions has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SOFTOX-ME News

Simply Wall St News

If You Had Bought SoftOx Solutions (OB:SOFTOX-ME) Stock A Year Ago, You'd Be Sitting On A 38% Loss, Today

View our latest analysis for SoftOx Solutions With just øre5,613,136 worth of revenue in twelve months, we don't think the market considers SoftOx Solutions to have proven its business plan. … It seems likely some shareholders believe that SoftOx Solutions will significantly advance the business plan before too long. … With the stock down 3.5% over the last three months, the market doesn't seem to believe that the company has solved all its problems.

Simply Wall St -

Did SoftOx Solutions AS (OB:SOFTOX-ME) Insiders Buy Up More Shares?

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' See our latest analysis for SoftOx Solutions SoftOx Solutions Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by Non-Executive Director Kristian Almas for øre6.3m worth of shares, at about øre22.00 per share. … Insider Ownership of SoftOx Solutions I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. … Once you factor in the high insider ownership, it certainly seems like insiders are positive about SoftOx Solutions.

Simply Wall St -

What Type Of Shareholder Owns SoftOx Solutions AS's (OB:SOFTOX-ME)?

The big shareholder groups in SoftOx Solutions AS (OB:SOFTOX-ME) have power over the company. … SoftOx Solutions is not a large company by global standards. … See our latest analysis for SoftOx Solutions

Simply Wall St -

SOFTOX-ME Company Info

Description

SoftOx Solutions AS, together with its subsidiaries, operates as a medtech company in Norway. Its SoftOx technology kills the microorganisms in biofilms by acting on various microbial components. The company engages in the development of SoftOx Wound Irrigation Solution that is under preclinical studies for the prevention and treatment of infections on breached or compromised skin, including acute wounds and skin lesions in patients with eczema; and SoftOx Biofilm Eradicator, which is in preclinical studies to treat biofilm infections in non-healing chronic wounds. The company was founded in 2012 and is headquartered in Oslo, Norway.

Details
Name: SoftOx Solutions AS
SOFTOX-ME
Exchange: OB
Founded: 2012
NOK112,874,400
4,626,000
Website: http://www.soft-ox.com
Address: SoftOx Solutions AS
Hoffsveien 1A,
Oslo,
Oslo, 0275,
Norway
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OB SOFTOX-ME Share Capital Oslo Bors NO NOK 01. Jun 2018
Number of employees
Current staff
Staff numbers
10
SoftOx Solutions employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/14 23:14
End of day share price update: 2019/09/13 00:00
Last earnings filing: 2019/06/28
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.